CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Lipid modification - primary and secondary CVD prevention - Management
When should I consider intensifying lipid modification therapy for secondary prevention of cardiovascular disease?
- Consider higher intensity lipid modification therapy if total cholesterol of less than 4 mmol/L or low-density lipoprotein cholesterol of less than 2 mmol/L has not been achieved.
- Any decision to offer a higher intensity statin should take into account patient preference and tolerability, comorbidities, multiple drug therapy, and the benefits and risks of treatment.
- A target total cholesterol level of less than 5 mmol/L should be used as the minimum standard of care for all people with cardiovascular disease. Wherever possible, the optimal treatment targets should be achieved.
In depth
© NHS Institute for Innovation and Improvement